Stock Review: $ZYXI
OVERALL THOUGHTS 💭
- I’m now watching this one closely. If the market wasn’t in a bad downtrend, I’d buy this stock rn.
- Their Q1 22’ report beat Q1 21’ in revenue, net income, and EPS. Meaning their FY 22’ is on track to beat FY 21’ in all 3 categories.
- CEO gave great FY 2022 guidance.
- Announced Share Buyback Program up to $10M over next 12 months.
2022: $150M - $170M (guidance)
2022: on track to beat 2021
EARNINGS PER SHARE (EPS):
2022: on track to beat 2021
$256.9M. Small cap. Lots of room for rapid stock price (and overall company) growth.
From CEO: “March saw the largest number of orders in the Company's history, and we are expecting continued growth throughout all of 2022. We recently announced a stock buyback program of up to $10 million over the next 12 months to signal our confidence in the Company's long-term strategy. We believe that the decision will ultimately drive shareholder value and have already repurchased approximately $5 million from April 12th through April 27th, 2022.
Full year 2022 revenue is estimated in the range of $150-$170 million and Adjusted EBITDA between $25 and $35 million. Profitability is expected to grow as sales reps become more efficient, further highlighting the anticipated EBITDA growth in 2022.
The estimated range for second quarter 2022 revenue is between $35.0 and $38.0 million, an increase of approximately 18% from 2Q21.
Second quarter 2022 Adjusted EBITDA is estimated to range between $4.0 and $6.0 million, an increase of approximately 5% from 2Q21.
Zynex, Inc is an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring.
ONE LARGE EXTERNAL FACTOR?
No. I could not locate any external factor that alone heavily affects their earnings.
STOCK PRICE UPTREND:
Price has increased from $0.27 to $6.58 since Dec 2016.
FOLLOW ME 😎
To hear about more high-potential stocks EARLY, long before they produce life-changing returns.
I wouldn’t call $ZYXI innovative, they sell cheap tens units to medicare patients and sometimes over bill
There been a few shorts on it’s tails and I think for a good reason
I would be very careful with this one
@from100kto1m I agree, just took a lot of the description off their website lol however, a good reason they have shorts now is because their stock price appreciated over 100x between 2016-2020. That’s incredibly fast appreciation, almost too fast really. All we know right now is that the company is growing consistently so let’s see if they can keep it up. I bet if they keep up this growth for the next 5-10 years, their stock price will appreciate tremendously from here. Not in the short term tho, the market is trash and we don’t know how long that’ll last